VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT: CVM) today announced that Dr. Daniel Zimmerman, its Senior Vice President of Research, Cellular Immunology, is presenting at the 17th Annual World Vaccine Congress held in Washington D.C. on April 12, 2017. The conference runs from April 10-12, 2017. The title of his presentation is “Unmet need for therapeutic vaccines for autoimmune conditions with emphasis on arthritis – and a look into the future.”
At the conference, Dr. Zimmerman is presenting data supporting a potentially novel approach to fighting the inflammation in the joints caused by rheumatoid arthritis. He introduced animal data that demonstrates that using CEL-SCI’s LEAPS CEL-4000 Rheumatoid Arthritis treatment vaccine downregulates pro-inflammatory T-cell responses and upregulates anti-inflammatory T-cell responses. This finding was confirmed by an examination of cytokines in the serum of the animals and by earlier data on CEL-4000 and CEL-2000 in the two animal models examined. Information on other autoimmune conditions showing either a Th1 or Th17 signature cytokine profile was cited and supportive as well.
Dr. Zimmerman said, “I believe based on the above findings and observations of others that the future of this novel approach using LEAPS therapeutic vaccines could be expanded to other autoimmune conditions with similar Th1 and Th17 signature cytokine phenotypes including multiple sclerosis, autoimmune uveitis, and type I diabetes.”
About the World Vaccine Congress
The World Vaccine Congress is now well-established as the must attend global vaccine event each year, where leaders of the industry come to discuss science and do business. Now in its 17th year, the event in 2017 will bring over 700 senior vaccine executives to learn, meet and form partnerships. - See more at: http://www.terrapinn.com/conference/world-vaccine-congress-washington/our-Story.stm#sthash.Cjiak553.dpuf
L.E.A.P.S. (Ligand Epitope Antigen Presentation System) is a CEL-SCI patented platform technology designed to stimulate antigen-specific immune responses in T-cells using synthetic peptides. LEAPS constructs physically link the antigenic peptide with a T-cell binding ligand and are delivered directly to the recipient immune system by injection or mucosal absorption, potentially enhancing T-cell responses to a particular antigen.
CEL-SCI's work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words "intends," "believes," "anticipated," "plans" and "expects," and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI's filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K and 10-K/A for the year ended September 30, 2016. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.